We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Biomarkers Correlated with Idiopathic Inflammatory Myopathy

By LabMedica International staff writers
Posted on 25 Sep 2018
Patients with idiopathic inflammatory myositis (IIM) typically present with muscle weakness, myalgia and in case of dermatomyositis (DM) also skin involvement. More...
Arthralgia is often present, but the articular manifestations are usually mild and non-destructive.

As rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are not routinely tested in idiopathic inflammatory myositis (IIM), little is known about their prevalence and clinical implications in this patient group. In anti-synthetase syndrome (ASS), presence of ACPA is reportedly associated with more severe and erosive arthritis.

Medical scientists at the University Hospitals Leuven (Leuven, Belgium) analyzed serum samples from 121 patients. Thirty diagnosed with polymyositis, 41 with dermatomyositis, 37 with ASS, five with necrotizing autoimmune myopathy or seven with overlap myositis and one with inclusion body myositis. RF was evaluated by nephelometry; anti-CCP antibodies were identified using fluoro enzyme immunoassays. Values above 40 IU/mL and 7 U/mL were considered positive for RF and ACPA, respectively.

The investigators observed no significant differences were observed between RF-positive and RF- negative IIM patients. The prevalence of RF and ACPA was 9.09% and 4.96%, respectively. The team observed a trend for RF-positive IIM patients to be older than RF-negative IIM patients and to more frequently carry ACPA antibodies and have lower forced expiratory volume in 1 second (FEV1) values (72% versus 88%). There was no statistically significant difference between patients who tested positive for both RF and ACPA, and patients who tested negative for both antibodies. The presence of RF or ACPA was not significantly associated with interstitial lung disease.

The authors concluded that their study demonstrated that RF and ACPA are prevalent in patients with IIM, but the detected prevalence is lower than the prevalence reported in previous studies in connective tissue diseases including IIM. Their results did not show a clear association between RF or ACPA positivity and specific clinical features or the occurrence of ILD or arthritis. The study was published originally published online on July 25, 2018, in the journal RMD Open.

Related Links:
University Hospitals Leuven


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Electrolyte Analyzer
BKE-B
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.